<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04885491</url>
  </required_header>
  <id_info>
    <org_study_id>2020-PDNO-002</org_study_id>
    <nct_id>NCT04885491</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Covid-19 Patients With aPH</brief_title>
  <official_title>An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of the Two Regioisomers 1-(Nitrosooxy)Propan-2-ol and 2- (Nitrosooxy)Propan-1-ol (PDNO) Infusion in Covid-19 Patients With Acute Pulmonary Hypertension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Attgeno AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vinnova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Attgeno AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicentre study evaluating the effect, safety and tolerability of&#xD;
      the two regio isomers 1-(nitrosooxy)propan-2-ol and 2- (nitrosooxy)propan-1-ol (PDNO)&#xD;
      infusion given to COVID-19 patients with acute pulmonary hypertension (aPH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multicentre study to evaluate the efficacy, safety and tolerability of&#xD;
      the two regio isomers 1-(nitrosooxy)propan-2-ol and 2- (nitrosooxy)propan-1-ol (PDNO)&#xD;
      infusion given to COVID-19 patients with acute pulmonary hypertension (aPH) and/or Acute Cor&#xD;
      Pulmonale (ACP). PDNO is developed to be used as part of peri- and post-operative pulmonary&#xD;
      hypåertension (PH) treatment in adults in conjunction to heart surgery, to selectively&#xD;
      decrease pulmonary arterial pressure and improve Right ventricular (RV) function and&#xD;
      oxygenation. Current treatment options for aPH in patients with COVID-19 are limited. In&#xD;
      addition to the hemodynamic effects, it is believed to be beneficial to use an&#xD;
      iv-administered lung-selective Nitrogen Oxide (NO) donor that will more effectively reach&#xD;
      affected areas in the lung and give maximal NO-exposure to the endothelium. The potential&#xD;
      antiviral effects of NO, by inhibition of receptor binding and inhibition of earlystage virus&#xD;
      replication, are also part of the rational to evaluate the benefits of using of PDNO in&#xD;
      COVID-19 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">August 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Starting with an observational period with placebo treatment and then starting the treatment with PDNO</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The treatment is blinded for the subjects.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of PDNO on in patients with Covid-19 and pulmonary hypertension (PH).</measure>
    <time_frame>During 24 hours</time_frame>
    <description>Pulmonary vascular resistance (PVR) and mean pulmonary artery pressure (MPAP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of PDNO in patients with COVID-19.</measure>
    <time_frame>Through study completion during 30 days</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate general clinical outcome</measure>
    <time_frame>Through study completion during 30 days</time_frame>
    <description>Number of participants respectively with the following outcome dead, intubated at the ICU, non-intubated at the ICU, discharged from ICU to other hospital care or discharged to home.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To decide the time to non-SARS-CoV-2 infection</measure>
    <time_frame>7 days</time_frame>
    <description>Levels of SARS-CoV-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the change in troponin I/T and BNP/NT-proBNP after PDNO dosing in patients with Covid-19 and PH</measure>
    <time_frame>7 days</time_frame>
    <description>Levels of troponin and BNP/NT-proBNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of PDNO</measure>
    <time_frame>1 day</time_frame>
    <description>The pulmonary resistance</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To assess presence of SARS-CoV-2 virus</measure>
    <time_frame>7 days</time_frame>
    <description>Levels of SARS-CoV-2 virus in plasma and in secret</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Observational period with placebo treatment and then experimental treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational period (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Starting with observational period with placebo treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Observational period with placebo infusion during 2 hours.</description>
    <arm_group_label>Treatment arm</arm_group_label>
    <other_name>Sodium Chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDNO</intervention_name>
    <description>Infusion of PDNO. Starting with dose escalating and then treatment up to 8 hours.</description>
    <arm_group_label>Observational period (placebo)</arm_group_label>
    <other_name>Nitrosooxypropanol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand and willing to sign an ICF.&#xD;
&#xD;
          2. Male and female patients, age at least 18 years.&#xD;
&#xD;
          3. Diagnosed with COVID-19 at admission to the ICU.&#xD;
&#xD;
          4. Diagnosed with echocardiographic signs of pulmonary artery systolic pressure (PASP)&#xD;
             &gt;40 mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of chronic PH, as judged by the Investigator at screening&#xD;
&#xD;
          2. Known New York Heart Association (NYHA) Functional Class III or IV symptoms&#xD;
&#xD;
          3. Left heart failure with ejection fraction (EF) &lt; 35 %&#xD;
&#xD;
          4. Acute coronary syndrome&#xD;
&#xD;
          5. Body Mass Index (BMI) &gt; 40 kg/m2&#xD;
&#xD;
          6. Estimated glomerular filtration rate (eGFR) &lt; 30 mL/min&#xD;
&#xD;
          7. MetHb &gt;3%&#xD;
&#xD;
          8. PCO2 &gt; 7&#xD;
&#xD;
          9. Indication of liver disease, defined by serum levels of either alanine&#xD;
             aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP)&#xD;
             above 3 x upper limit of normal (ULN) at screening&#xD;
&#xD;
         10. Haemoglobin &lt;80 g/dL&#xD;
&#xD;
         11. Thrombocytopenia (platelet count &lt;80000/mm3)&#xD;
&#xD;
         12. Prothrombin time International ratio (INR) &gt; 1.4&#xD;
&#xD;
         13. Pregnancy, or a positive pregnancy test&#xD;
&#xD;
         14. Ongoing daily treatment the last 3 days with non-steroidal anti-inflammatory drugs&#xD;
&#xD;
         15. Known active malignancy within the past 3 years&#xD;
&#xD;
         16. History of allergy/hypersensitivity to PD or ongoing allergy/hypersensitivity or&#xD;
             history of hypersensitivity to drugs with a similar chemical structure or class to&#xD;
             PDNO.&#xD;
&#xD;
         17. History of any other clinically significant disease or disorder&#xD;
&#xD;
         18. Participation in any interventional clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanna Savilampi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Örebro County</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piotr Harbut, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danderyd Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claes Jagensjö, MPHARM</last_name>
    <phone>+46761464911</phone>
    <email>claes.jagensjo@attgeno.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Danderyd Hospital</name>
      <address>
        <city>Danderyd</city>
        <zip>18257</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Piotr Harbut, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <zip>70116</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Savilampi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

